Hormone therapy before surgery for lobular breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 50 or older and have gone through menopause.
- You have been diagnosed with lobular breast cancer that is stage cT2 or cT3 and has not spread to many lymph nodes (N0 or N1).
- Your tumor is estrogen receptor positive (ER+) and HER2 negative.
- You are healthy enough for breast-conserving surgery and choose to have it.
- You have not had breast cancer on the same side before.
- You do not have advanced cancer (stage 4 or very large lymph node involvement) and are not a candidate for chemotherapy before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a hormone-blocking medicine (endocrine therapy) given before surgery affects a marker called Ki67 in your breast cancer cells. The goal is to see if the medicine can slow the growth of the cancer, which may help doctors choose the best treatment for you.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests two different chemotherapy drugs, lobaplatin or carboplatin, given before surgery to shrink HER2-positive breast tumors. It aims to see which drug works better and is safer for you.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This trial tests a new combination of treatments given before surgery for hormone receptor positive, HER2 negative breast cancer. It uses stereotactic body radiation therapy (SBRT), chemotherapy, and an investigational drug called AK112 to shrink tumors and make surgery easier.
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.